GlassScriptPhysician profile
Deshawndranique D Gray
NPI 1336159300
$1,729.90
in general payments reported to CMS, 2019-2025
27 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $102 · 2021: $126 · 2022: $395 · 2023: $198 · 2024: $123 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $248.66 | 2019-2020 | |
| Abbvie INC. | $180.72 | 2019-2023 | |
| Exeltis, USA INC. | $173.77 | 2019-2025 | Slynd |
| Myovant Sciences INC. | $156.39 | 2021-2022 | |
| Organon LLC | $108.85 | 2021-2025 | Nexplanon, Nuvaring |
| Astellas Pharma US INC | $102.78 | 2022-2025 | Veozah |
| Teleflex LLC | $89.96 | 2019 | |
| Ethicon US, LLC | $87.99 | 2022-2025 | Stratafix |
| Merck Sharp & Dohme LLC | $69.43 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.56 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $62.48 | 2022-2023 | |
| Mission Pharmacal Company | $49.77 | 2019 | |
| Hologic Sales and Service, LLC | $42.38 | 2022-2024 | Acessa Provu System |
| Mylan Pharmaceuticals INC. | $34.01 | 2021 | |
| Meditrina | $31.20 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30.69 | 2019 | |
| Convatec INC. | $22.42 | 2023 | |
| Idorsia Pharmaceuticals US INC | $21.25 | 2023 | Quviviq |
| Pacira Pharmaceuticals Incorporated | $20.17 | 2024 | Exparel |
| Novo Nordisk INC | $17.66 | 2024 | |
| Pfizer INC. | $17.02 | 2023 | |
| Lilly USA, LLC | $16.94 | 2025 | Zepbound |
| Amag Pharmaceuticals, INC. | $16.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.58 | 2024 | Farxiga |
| Horizon Therapeutics Plc | $15.47 | 2019 | |
| Shield Therapeutics INC | $15.24 | 2025 | |
| Therapeuticsmd, INC. | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deshawndranique Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.